Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > A trend

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Sep 21, 2020 10:02pm

117 Views

Post# 31595761

RE:A trend

:) The king is dead, long live the king.

I don't think even skeptics like me are writing off NASH yet. It's more like we have two pretenders to the throne atm.

longterm56 wrote: Egrifta faded into the background when Trogarzo came on the scene, Trogarzo fades into the background when NASH came on the scene, and already the posts here are starting to fade NASH into the background because oncology. Anyone see a pattern here? I think we have had > 12 "catalysts" come and go ... so I guess it's time to think up new ones ...

-LT